Myelodysplastic Syndrome
Conference Coverage
Predicting therapy-related myeloid neoplasms
Photo courtesy of MD Anderson Cancer Center SAN DIEGO―Clonal hematopoiesis could be used as a predictive marker to identify cancer patients at...
News
Decitabine produces responses in high-risk MDS, AML
receiving chemotherapy Photo by Rhoda Baer Patients with TP53-mutated myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) may benefit...
News
Inflammation may predict transformation to AML
Inflammatory signaling in mesenchymal niche cells can be used to predict the transformation from pre-leukemic syndrome to acute myeloid leukemia (...
News
Teva launches generic imatinib tablets in US
Photo by Steven Harbour Teva Pharmaceutical Industries Ltd.
News
Method provides more accurate diagnosis of MDS, team says
Next-generation sequencing (NGS) of cell-free DNA should be the method of choice to confirm the diagnosis of myelodysplastic syndromes (MDS),...
News
Radiologists no longer have higher risk of cancer-related death
Photo by Rhoda Baer Radiologists who graduated from medical school after 1940 do not have an increased risk of dying from radiation-related...
News
Immunotherapy may benefit relapsed HSCT recipients
Photo from Business Wire Results of a phase 1 study suggest that repeated doses of the immunotherapy drug ipilimumab is a feasible treatment...
News
Ipilimumab may restore antitumor immunity after relapse from HSCT
Key clinical point: Anti-CTLA-4 therapy may restore graft-versus-tumor effect in patients with hematologic malignancies relapsed after allogeneic...
News
Midostaurin cut organ damage in systemic mastocytosis
Key clinical point: Midostaurin helped to resolve organ damage related to mastocytosis. Major finding: In all, 45% of patients had complete...
News
Lenalidomide eliminated transfusion dependence for a minority of non-del(5q) MDS patients
Key clinical point: Lenalidomide usually does not free patients with lower-risk non-del(5q) myelodysplastic syndromes who are refractory to or...
News
Study: CMV doesn’t lower risk of relapse, death
Small studies have suggested that early cytomegalovirus (CMV) reactivation may protect against leukemia relapse and even death after hematopoietic...